Effectiveness
PFA was noninferior to pooled thermal ablation in ADVENT; direct comparisons with RF and cryoballoon answer different questions. [4][5][2]
PULSED FIELD ABLATION / TREATMENT CHOICES
PFA vs radiofrequency and cryoballoon ablation: which fits your AF treatment?
Safety
Less collateral tissue injury does not mean risk-free. Catheter complications and rare PFA-specific injuries still matter. [1]
Aftercare
PFA does not remove the need for rhythm monitoring or a clinician-led medication and anticoagulation plan. [6]
Pulsed field ablation (PFA) is an effective alternative to heat-based radiofrequency and freezing-based cryoballoon ablation for atrial fibrillation. Its main attraction is rapid treatment with less collateral injury to nearby tissues—not a guarantee of a higher success rate. For paroxysmal AF, randomized trials support PFA as a reasonable option, but do not establish it as the best treatment for everyone. Your AF pattern, the planned procedure, the device and the team's experience should guide the choice. [1][2][3][4][5]
Three ways to treat AF triggers—not three different operations
All three are catheter procedures rather than open-heart surgery. For AF, the central treatment is pulmonary vein isolation (PVI): blocking abnormal electrical signals around the veins that enter the left atrium. The main difference is the energy used to create that block. [7][2][3][8]
| Feature | Pulsed field ablation | Radiofrequency ablation | Cryoballoon ablation |
|---|---|---|---|
| How it works | Electrical pulses damage targeted heart cells through electroporation, rather than heating or freezing them. [7][6][5] | Heat is delivered through a catheter; point-by-point RF is one established approach. [7][6][5] | A balloon delivers freezing energy around the pulmonary veins. [7][6][5] |
| Main practical benefit | Rapid energy delivery and a favorable profile for injury to nearby structures, particularly the esophagus. [9][1][3][6][5] | An established mapped, point-by-point option; RF can also be delivered alongside PFA by some dual-energy systems when needed. [9][1][3][6][5] | An established balloon-based PVI workflow that simplifies treatment around the veins. [9][1][3][6][5] |
| What the direct trials show | Effective at one year; not shown superior to modern CLOSE-protocol RF in BEAT PAROX-AF. [2][5] | In BEAT PAROX-AF, one-year single-procedure success was similar to PFA; superiority of PFA was not established. [2][5] | SINGLE SHOT CHAMPION found fewer monitored recurrences with PFA than cryoballoon in its study population. [2][5] |
| Tradeoffs | Still carries catheter-related risks; coronary spasm and hemolysis-related kidney injury have been reported. X-ray exposure may be longer than with heat ablation. [9][1][3][6][5] | Thermal tissue injury remains a consideration. PFA did not eliminate the need for RF in every procedural strategy. [9][1][3][6][5] | Balloon positioning depends on vein anatomy; thermal injury to adjacent structures remains a consideration. [9][1][3][6][5] |
| Aftercare | A medication and rhythm-monitoring plan is still needed. [6] | A medication and rhythm-monitoring plan is still needed. [6] | A medication and rhythm-monitoring plan is still needed. [6] |
How likely is treatment to work? Read the right comparison
The most useful number is from a study that resembles your AF type and planned procedure. 'Success' can mean no symptoms, no detected rhythm episode, or a stricter combination that also excludes extra medicines, cardioversion and repeat ablation. These measures are not interchangeable. [2][10][4][5]
| Study and patients | Result | What it means for your choice |
|---|---|---|
| ADVENT, 2023: drug-refractory paroxysmal AF; FARAPULSE PFA; 305 PFA and 302 pooled RF/cryo participants | One-year freedom from the failure composite: 204 PFA and 194 thermal patients had no events; estimated probabilities 73.3% versus 71.3%. Difference 2.0 percentage points; 95% Bayesian credible interval −5.2 to 9.2. [4][8] | PFA met the trial's noninferiority criterion. This is not proof of superiority, and the pooled comparison cannot tell you whether PFA beats RF or cryoballoon separately. [4][8] |
| BEAT PAROX-AF, 2026: symptomatic drug-resistant paroxysmal AF; 292 randomized, 289 analyzed | One-year single-procedure success: 112/145 (77.2%) PFA versus 111/143 (77.6%) CLOSE-protocol RF. Adjusted difference 0.9 percentage points; 95% confidence interval −8.2 to 10.1; P=0.84. [5] | A direct comparison with modern point-by-point RF did not show PFA to be more effective. The analyzed RF group was 144, but the published efficacy result uses 143; the abstract does not explain that missing observation. [5] |
| SINGLE SHOT CHAMPION, 2025: symptomatic paroxysmal AF in Switzerland; 105 patients per group, all with an implanted rhythm monitor | First atrial tachyarrhythmia recurrence during days 91–365: 39 PFA and 53 cryoballoon patients. Kaplan–Meier incidence 37.1% versus 50.7%; difference −13.6 percentage points; 95% confidence interval −26.9 to −0.3. [2] | The primary noninferiority criterion was met; the study also reported P=0.046 for superiority. This is evidence of fewer recurrences in this particular PFA–cryo comparison, not a universal ranking of ablation methods. [2] |
ADVENT's percentages are estimated one-year probabilities, not simple fractions of the original groups. Success meant freedom from all of these failure events: initial procedural failure, rhythm recurrence after a three-month blanking period, antiarrhythmic drug use, cardioversion or another ablation. BEAT used a two-month blanking period and a different composite. SINGLE SHOT CHAMPION measured recurrence with continuous monitoring and used a 20-percentage-point noninferiority margin. Do not compare the headline percentages across studies as though the patients and monitoring were identical. [2][4][5]
Longer follow-up is emerging. In the ADVENT-LTO participating subset—183 PFA and 181 thermal patients—four-year treatment success was 72.8% versus 64.3% (P=0.12). That primary comparison did not establish superiority, and the smaller participating cohort is not the full original randomized population. No method guarantees that AF will never recur. [11]
ADVENT tested whether PFA was not unacceptably worse than pooled thermal ablation, using prespecified absolute margins of 15 percentage points for effectiveness and 8 for safety. Noninferiority does not mean identical results or superiority. The primary design used Bayesian estimates with noninformative priors; censored follow-up was included by multiple imputation using a Bayesian piecewise exponential survival model. The published design specified 72-hour Holter recordings at 6 and 12 months plus weekly and symptom-triggered transmissions after the 90-day blanking period—not continuous implanted monitoring. Missing follow-up therefore involves model assumptions, and monitoring intensity affects how often recurrence is detected. [12]
The abstract reports 305 PFA and 302 thermal participants. The registry labels the primary outcome population modified intention-to-treat (MITT), while its total enrollment of 706 also includes 80 roll-in patients and 19 randomized patients who withdrew before the procedure. These totals answer different questions: 706 is not the denominator for the quoted treatment probabilities, and 204/305 and 194/302 are not the published probability estimates. [8][4]
PFA's tissue-sparing advantage is valuable—but it is not risk-free
PFA's appeal is more than being new. Electrical pulses offer a way to treat heart tissue while limiting collateral damage to nearby structures. In MANIFEST-17K, no esophageal complications, pulmonary vein stenosis or persistent phrenic nerve palsy were reported among 17,642 patients treated with a pentaspline PFA catheter at 106 centers. That is reassuring real-world evidence for these specific injuries, not a promise that they can never occur. [1][3]
The same registry reported major complications in 173/17,642 patients, approximately 1%. These included tamponade—fluid around the heart requiring urgent treatment—in 63/17,642 (0.36%), vascular events in 53/17,642 (0.30%), stroke in 22/17,642 (0.12%) and death in 5/17,642 (0.03%). Coronary artery spasm occurred in 25/17,642 (0.14%), and hemolysis-related acute kidney failure requiring dialysis in 5/17,642 (0.03%). Hemolysis means breakdown of red blood cells. The registry was not a randomized comparison with RF or cryo; event categories should not be added together as if they were necessarily separate patients. [1]
In randomized ADVENT, the serious device- or procedure-related safety endpoint occurred in 6 PFA patients and 4 thermal patients. Estimated incidences were 2.1% and 1.5%, with a difference of 0.6 percentage points and a 95% Bayesian credible interval of −1.5 to 2.8. PFA met noninferiority, not superiority, for this overall endpoint. The registry and trial therefore answer different safety questions. [1][4]
PFA also offers rapid energy delivery. But the pulses occupy only part of a procedure that still requires anesthesia, catheter placement, imaging and monitoring. A shorter energy-delivery stage does not by itself prove an earlier return to work. Depending on the system and workflow, fluoroscopy exposure may be longer than with RF. [3]
When each approach may fit
Symptomatic paroxysmal AF, especially after a medicine has failed or caused side effects
PFA, RF and cryoballoon are reasonable options to discuss with an electrophysiologist. PFA's tissue-sparing profile may be attractive; modern RF remains supported by direct randomized evidence, and cryoballoon offers an established balloon-based PVI approach. The evidence does not make a well-planned RF or cryoballoon procedure an inferior choice simply because PFA is newer. [7][2][6][5]
A procedure that needs more than a standard PVI workflow
The lesion plan and catheter matter, not just the energy label. Point-by-point RF and balloon-based treatment are different workflows. Some systems, such as Affera/Sphere-9, allow the team to use both PFA and RF in one procedure. A 'PFA procedure' therefore does not always mean that no heat is used. [9][13][6][5]
Persistent AF
Use persistent-AF evidence, not ADVENT's paroxysmal-AF percentages. In the single-arm ADVANTAGE AF study of FARAPULSE PVI plus posterior wall ablation, the one-year primary effectiveness estimate was 63.5%, with a 97.5% one-sided lower confidence limit of 57.3%. There were 260 treatment patients and 79 roll-in patients. This supports an option for persistent AF but does not establish superiority over thermal ablation. [10]
Treatment in a particular country or with a particular device
Indications differ. The FDA's January 12, 2026 FARAPULSE supplement includes pulmonary-vein and posterior-wall isolation for drug-refractory symptomatic persistent AF with episode duration less than one year, alongside the paroxysmal indication. This does not make every PFA system approved for every AF pattern or lesion set. [14][8]
Considering ablation before trying an antiarrhythmic drug
Ablation can be considered first-line in selected symptomatic patients; you do not necessarily have to cycle through several medicines first. That broader treatment choice is separate from the eligibility criteria of a particular PFA device or trial. The assessment should establish your AF pattern, symptoms and heart function before choosing the technology. [7][14][8]
Recovery and medicines: what does not change with PFA
Cleveland Clinic's PFA patient information describes three to six hours of bed rest after the procedure and discharge on the same or next day. This is a typical pathway, not a guarantee. The international consensus also allows same-day discharge for selected AF-ablation patients, so this is not an advantage unique to PFA. Follow your own team's restrictions for the groin puncture, activity and travel; this page does not set a personal return-to-work or flight date. [3][6]
Do not stop anticoagulation because you feel better or your rhythm appears normal. The 2024 international ablation consensus recommends at least two months of anticoagulation after AF ablation, with longer-term treatment based on stroke risk rather than presumed ablation success. Your clinician may prescribe a longer minimum under local guidance and your individual circumstances. [6]
Some patients continue antiarrhythmic medicines for several months to reduce early recurrences. Evidence supports reducing early episodes, not a guaranteed lasting benefit after the drugs are stopped. Follow-up and rhythm monitoring still matter even when symptoms improve; medicine changes belong in the treating team's plan. [6]
After treatment, facial drooping or arm weakness needs emergency help. New AF symptoms, bleeding or swelling at the groin, chest pain, dizziness or leg pain should be reported promptly to your care team. [3]
Real assessment routes—and what is known about cost
These are documented service examples, not rankings or endorsements. An assessment determines whether ablation is suitable and which energy source, device and follow-up plan fit your case. Trial success rates above are not these providers' own outcomes. [9][13][15]
Cleveland Clinic — Northeast Ohio assessment route
Cleveland Clinic reported routine atrial PFA use in May 2025, including FARAPULSE and the dual-energy Sphere-9/Affera system. Its arrhythmia service lists 800.659.7822 for Northeast Ohio. The Northeast Ohio assessment service can route your case to the appropriate team and treatment location. [13][20][17][19][21]
The official patient price-list page provides an individual estimator route; billing assistance is available at 216.445.6249 or 866.621.6385. Hospital/facility charges and some anesthesiology, radiology or laboratory services may be billed separately under the institution's general policy. [13][20][17][19][21]
The Harley Street Clinic, London — Dr Oliver Segal
HCA documented Affera PFA at The Harley Street Clinic in December 2025. Dr Oliver Segal's official profile lists electrophysiology and pulsed field ablation; his practice site specifically describes Affera-based PFA. Consultations are available through his practice, including telephone/video options; procedures take place at The Harley Street Clinic on Weymouth Street. Practice appointments: 020 3553 9370. [9][22][15][16][18]
The official HCA profile lists £350 for a new consultation and £350 for follow-up. These are consultation fees—not PFA treatment prices. HCA's self-pay team provides individual estimates; its general payment policy separates consultant fees from hospital charges. Use the written procedure-specific estimate to establish the final inclusions rather than treating a consultation price as an ablation price. [9][22][15][16][18]
The sources above do not establish that PFA is cheaper or more expensive than RF or cryoballoon for your treatment. Published general billing categories are not confirmed PFA package inclusions. A procedure-specific written estimate, issued after clinical assessment, is the actionable cost document. [16][17][18][19]
Arrange an electrophysiology assessment
Compare AF ablation options with Bookimed, or contact the documented provider assessment services below. Suitability and the final treatment plan depend on an electrophysiology assessment.
Sources and further reading
- MANIFEST-17K (2024): post-approval safety registry
- SINGLE SHOT CHAMPION (2025): PFA versus cryoballoon with continuous monitoring — primary abstract
- Cleveland Clinic: pulsed field ablation, recovery and precautions
- ADVENT (2023): randomized PFA versus pooled thermal ablation — primary abstract
- BEAT PAROX-AF (2026): PFA versus CLOSE-protocol radiofrequency — primary abstract
- 2024 EHRA/HRS/APHRS/LAHRS expert consensus — full text
- ESC (2024): international consensus on AF catheter ablation
- ClinicalTrials.gov NCT04612244: ADVENT protocol and reported results
- HCA Healthcare UK: Affera introduction at The Harley Street Clinic
- ADVANTAGE AF (2025): single-arm persistent-AF study — primary abstract
- ADVENT-LTO (2026): participating cohort at four years — primary abstract
- ADVENT rationale and design (2023): Bayesian methods, margins and monitoring
- Cleveland Clinic Consult QD (May 2025): institutional PFA use and systems
- FDA FARAPULSE supplement P230030S012 (January 12, 2026): approved indications
- Dr Oliver Segal: official practice, PFA and appointments
- HCA: payment policy and self-pay estimates
- Cleveland Clinic: patient price lists and individual estimates
- HCA: Dr Oliver Segal profile and consultation fees
- Cleveland Clinic: understanding separate bills and facility fees
- Cleveland Clinic: billing and financial assistance contacts
- Cleveland Clinic: arrhythmia assessment service
- HCA: self-pay enquiry route